Sök artiklar i SveMed+

Observera: SveMed+ upphör att uppdateras!



Behandling med dopaminagonister og udvikling af hjerteklapsygdom hos patienter med hyperprolaktinaemi
Engelsk titel: Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients Författare: Steffensen, Charlotte ; Maegbaek, Merete Lund ; Laurberg, Peter ; Andersen, Marianne ; Kistorp, Caroline ; Nörrelund, Helene ; Dal, Jakob ; Lunde Jörgensen, Jens Otto Språk: Dan Antal referenser: 21 Dokumenttyp: Översikt UI-nummer: 14017482

Tidskrift

Ugeskrift for Laeger 2014;176(1)58-60 ISSN 0041-5782 E-ISSN 1603-6824 KIBs bestånd av denna tidskrift Denna tidskrift är expertgranskad (Peer-Reviewed)

Sammanfattning

Dopamin agonist treatment and fibrotic heart valve disease in hyperprolactinaemia patients Treatment with dopamin agonists, particularly cabergoline, is the primary and preferred therapy for prolactinomas and symptomatic hyperprolactinaemia due to its effectiveness and tolerability. However, an association has been demonstrated between fibrotic heart valve disease and high-dose dopamin agonist use in patients with Parkinson’s disease in several echocardiographic studies. Such observations have prompted a number of studies of valvular function in cabergoline-treated hyperprolactinaemia patients. These studies have failed to show an increased prevalence of clinically significant valvular regurgitation.